ER Niacin

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC, University of Pennsylvania

Conditions

DyslipidemiaHypercholesteremiaHyperlipidemia

Phase 2

Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study

CompletedNCT00728910

University of PennsylvaniaDyslipidemia

Start: 2008-06-30End: 2009-08-31Updated: 2016-02-29

Phase 3

Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)

CompletedNCT00376584

Merck Sharp & Dohme LLCHypercholesteremia, Hyperlipidemia

Start: 2006-07-31End: 2007-01-31Updated: 2017-02-16